Shares of Revvity Inc. RVTY rallied 1.54% to $112.15 Friday, on what proved to be an all-around favorable trading session for ...

Jan 31 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its ...

Shares of Revvity Inc. RVTY slid 4.05% to $110.45 Thursday, on what proved to be an all-around dismal trading session for the ...

Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position ...

Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year ...

Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days. At Revvity, “impossible” is inspiration ...

KeyBanc analyst Paul Knight maintained a Buy rating on Revvity (RVTY – Research Report) today and set a price target of $145.00. The company’s shares closed last Friday at $126.13. Leverage ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Revvity, Inc. (RVTY) on Friday reported fourth-quarter net income of $94.6 million. The Waltham, Massachusetts-based company said it had net income ...

KeyBanc raised the firm’s price target on Revvity (RVTY) to $145 from $132 and keeps an Overweight rating on the shares. The firm notes that having pre-announced Q4 in mid-January, all eyes were ...

Revvity expects 2025 revenue to be in the range of $2.80 billion to $2.85 billion, compared with estimates of $2.87 billion. The company, however, beat fourth-quarter profit and revenue estimates ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...